Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice

Fig. 3

Effects of rivaroxaban on human EPC migration in vitro. a The cell viability assays evaluated the toxicity of rivaroxaban in late EPC proliferation. b The migratory function of EPCs was evaluated using a scratch injury model. Data are the mean ± SEM. (*P < 0.05 compared with control, # P < 0.05 compared with hyperglycemic conditions, n = 4 for each experiment)

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840